U.S. Markets open in 3 hrs 25 mins

Perrigo Company plc (PRGO)

New York Stock Exchange Consolidated Issue - New York Stock Exchange Consolidated Issue Delayed Price. Currency in USD
Add to watchlist
77.42-1.02 (-1.30%)
At close: 4:02PM EDT

76.77 -0.65 (-0.84%)
Pre-Market: 4:40AM EDT

People also watch
MYLENDPALXNTEVAREGN
Full screen
Previous Close78.44
Open78.16
Bid76.79 x 100
Ask77.11 x 100
Day's Range77.15 - 78.30
52 Week Range63.68 - 99.14
Volume766
Avg. Volume1,692,178
Market Cap11.04B
Beta0.66
PE Ratio (TTM)-3.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.64 (0.81%)
Ex-Dividend Date2017-05-24
1y Target EstN/A
  • Reuters16 hours ago

    SAC Capital's Martoma fails to overturn U.S. insider trading conviction

    A divided federal appeals court on Wednesday upheld the insider trading conviction of Mathew Martoma, a former portfolio manager for billionaire Steven A. Cohen's SAC Capital Advisors LP, after the U.S. Supreme Court made such cases easier to pursue. The 2nd U.S. Circuit Court of Appeals in Manhattan found "overwhelming" evidence that a Michigan doctor received financial benefits from providing confidential information to Martoma about a 2008 Alzheimer's drug trial.

  • Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
    Zacksyesterday

    Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval

    Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.

  • Barrons.com10 days ago

    Perrigo: Still A Hard Pill To Swallow

    Perrigo (PRGO) got a big lift off last week’s second quarter financial results. The stock price had a 16% one-day surge after the drug maker posted quarterly financial results that beat estimates and raised its guidance. It offered a stark contradiction to other specialty drug makers, namely the dismal results posted earlier this month by Teva Pharmaceutical Industries (TEVA).